BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Portola Pharmaceuticals, Inc. 

270 East Grand Avenue

South San Francisco  California  94080  U.S.A.
Phone: 650-246-7000 Fax: 650-246-7376


SEARCH JOBS



Segment
Start Up





 Company News
Portola Pharmaceuticals, Inc. Announces Publication Of Phase 3 APEX Study Design And Rationale In American Heart Journal 4/14/2014 9:20:58 AM    More...
Portola Pharmaceuticals, Inc. Initiates Phase 2 Study Of Andexanet Alfa, Potential First-In-Class Factor Xa Inhibitor Reversal Agent, And Factor Xa Inhibitor Edoxaban 3/27/2014 9:44:01 AM    More...
Portola Pharmaceuticals, Inc. Initiates Phase 3 Study Of Andexanet Alfa, Potential First-In-Class Factor Xa Inhibitor Reversal Agent, Under Accelerated Approval Pathway 3/19/2014 9:51:19 AM    More...
Portola Pharmaceuticals, Inc. Appoints John H. Johnson To Board Of Directors 3/18/2014 9:13:39 AM    More...
Portola Pharmaceuticals, Inc. Reports Fourth Quarter And Year-End 2013 Financial Results And Provides Corporate Update 2/28/2014 9:21:01 AM    More...
Portola Pharmaceuticals, Inc. To Present At The Cowen And Company 34th Annual Health Care Conference 2/24/2014 8:43:54 AM    More...
Portola Pharmaceuticals, Inc. To Announce Fourth Quarter And Year End 2013 Financial Results And Host Conference Call On Thursday, February 27, 2014 2/20/2014 8:48:12 AM    More...
Portola Pharmaceuticals, Inc. Enters Into Clinical Collaboration Agreement With Bayer HealthCare (BAY) And Janssen Pharmaceutical Inc. For Phase 3 Studies Of Andexanet Alfa*, Investigational Factor Xa Inhibitor Reversal Agent, And XARELTO® 2/3/2014 6:49:11 AM    More...
Portola Pharmaceuticals, Inc. Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb Company (BMY) And Pfizer Inc. (PFE) To Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With Eliquis 1/13/2014 9:41:59 AM    More...
Portola Pharmaceuticals, Inc. Announces Webcast Of Corporate Presentation On January 13, 2014 1/6/2014 9:19:15 AM    More...
12345678910

//-->